Street Calls of the Week
PARIS/MANCHESTER - Novacyt S.A. (EURONEXT GROWTH:ALNOV; AIM:NCYT), a molecular diagnostics company, will publish its unaudited interim results for the six months ended June 30, 2025, on Tuesday, September 30, the company announced on Thursday.
The France and UK-based company operates across three business segments: Clinical, Instrumentation, and Research Use Only. The Clinical segment offers diagnostic products for reproductive health, precision medicine, and infectious diseases. The Instrumentation division provides DNA sample preparation platforms and PCR machines, while the Research Use Only segment delivers services to the life sciences industry.
Novacyt maintains its headquarters in Le Vésinet, France, with additional offices in the UK, Singapore, the US, and Canada. The company reports having a commercial presence in more than 65 countries globally.
The announcement was made in a press release statement issued by the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.